Log in to save to my catalogue

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell mali...

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell mali...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e13fedf5b3e94ec1a443079d5e0501e7

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

About this item

Full title

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2023-06, Vol.14 (1), p.3423-3423, Article 3423

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrophage activation syndrome, and the lack of pathophysiologica...

Alternative Titles

Full title

Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e13fedf5b3e94ec1a443079d5e0501e7

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e13fedf5b3e94ec1a443079d5e0501e7

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-38723-y

How to access this item